NCT01613976View on ClinicalTrials.gov

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
Interventions
DRUG

Panobinostat

Trial Locations (6)

460-0001

Novartis Investigative Site, Nagoya

466-8650

Novartis Investigative Site, Nagoya

650-0017

Novartis Investigative Site, Kobe

980-8574

Novartis Investigative Site, Sendai

104-0045

Novartis Investigative Site, Chuo-ku

602-8566

Novartis Investigative Site, Kyoto

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY